초록 ▼

The invention provides improved methods for preparing hematopoietic cells for transplantation and the resulting improved hematopoietic cell compositions. The invention further relates to improved culture media and methods of culturing, processing, modulating, and expanding blood cell products for he

The invention provides improved methods for preparing hematopoietic cells for transplantation and the resulting improved hematopoietic cell compositions. The invention further relates to improved culture media and methods of culturing, processing, modulating, and expanding blood cell products for hematopoietic transplantation.

대표청구항 ▼

1. A composition comprising: a) about 5% to about 10% dextran;b) a chemically defined cell culture medium; andc) one or more cloned growth factors or one or more cytokines;wherein said composition does not contain fetal calf serum or an animal-derived lipid. 2. The composition of claim 1, wherein th

1. A composition comprising: a) about 5% to about 10% dextran;b) a chemically defined cell culture medium; andc) one or more cloned growth factors or one or more cytokines;wherein said composition does not contain fetal calf serum or an animal-derived lipid. 2. The composition of claim 1, wherein the dextran is selected from the group consisting of: dextran-1, dextran-10, dextran-20, dextran-30, and dextran-40. 3. The composition of claim 2, wherein the dextran is dextran-40. 4. The composition of 1, wherein the composition comprises about 10% dextran. 5. The composition of claim 1, wherein the chemically defined cell culture medium is selected from the group consisting of: Iscove's modified Dulbecco's medium (IMDM), Roswell Park Memorial Institute medium (RPMI) 1640 medium, McCoy's 5A medium, minimum essential medium alpha medium (alpha-MEM), basal medium Eagle (BME), Fischer's medium, medium199, F-12K nutrient mixture medium (Kaighn's modification, F-12K), and X-vivo 20. 6. The composition of claim 1, wherein the one or more cloned growth factors or cytokines are selected from the group consisting of: flt3-ligand (FLT3); thrombopoietin (TPO), stem cell factor (SCF), epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), basic fibroblast growth factor (bFGF), interleukin-3 (IL3), interleukin-6 (IL6), and interleukin-9 (IL9). 7. The composition of claim 1, further comprising an agent selected from the group consisting of a cAMP analogue or enhancer, a Gα-s activator, and a prostaglandin pathway agonist. 8. The composition of claim 7, wherein the prostaglandin pathway agonist selectively binds the prostaglandin E2 (PGE2) EP2 or the PGE2 EP4 receptor. 9. The composition of claim 7, wherein the prostaglandin pathway agonist comprises PGE2, or a PGE2 analogue or derivative. 10. The composition of claim 7, wherein the prostaglandin pathway agonist is selected from the group consisting of: PGE2, 16, 16-dmPGE2, 15(S)-15-methyl PGE2, 20-ethyl PGE2, and 8-iso-16-cyclohexyl-tetranor PGE2. 11. The composition of claim 7, wherein the prostaglandin pathway agonist comprises 16, 16-dmPGE2. 12. The composition of claim 1, further comprising a population of cells. 13. The composition of claim 12, wherein the population of cells is selected from the group consisting of: bone marrow cells (BMCs), umbilical cord blood cells (UCBCs), placental blood cells, mobilized peripheral blood cells (mPBCs), hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), and CD34+ cells. 14. The composition of claim 13, wherein the HSCs comprise a purified population of CD34+ cells. 15. The composition of claim 1, wherein the chemically defined cell culture medium comprises Iscove's modified Dulbecco's medium (IMDM), bovine serum albumin, insulin, transferrin, and vitamins. 16. A method comprising: thawing a whole cord blood sample, transferring the sample into a culture medium comprising the composition of claim 1, and modulating the sample in the culture medium by contacting the sample with an agent that modulates a prostaglandin pathway for a duration of about 1 to about 24 hours, at a temperature of about 25° C. to about 37° C. comprising a total nucleated cell (TNC) of at least 70%, wherein the sample is not subject to enrichment. 17. A composition comprising: a) about 5% to about 10% polysaccharide;b) a chemically defined cell culture medium; andc) one or more cloned growth factors;wherein said composition does not contain fetal calf serum; wherein the composition comprises: Calcium Chloride Anhydrous; Cupric Sulfate; Ferric Nitrate; Ferric Sulfate; Potassium Chloride; Magnesium Chloride; Magnesium Sulfate; Sodium Chloride; Sodium Bicarbonate; Sodium Phosphate Monobasic; Sodium Phosphate dibasic; Zinc Sulfate; D-Glucose (Dextrose); Phenol Red; 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES); Sodium Hypoxanthine; Linoleic acid; DL-68-Thioctic Acid; Sodium Putrescine; Putrescine 8 Sodium Selenite; Sodium Pyruvate; Alanine; Arginine; Asparagine; Aspartic acid; Cysteine; Cysteine; Glutamic acid; Glutamine; Glycine; Histidine; Isoleucine; Leucine; Lysine; Methionine; Phenylalanine; Proline; Serine; Threonine; Tryptophan; Tyrosine; Valine; Biotin; D-Calcium panthenate; Choline chloride; Folic acid; i-Inositol; Niacinamide; Pyridoxine; Riboflavine; Thiamine; Thymidine; and Vitamin B12. 18. The composition of claim 17, wherein the composition comprises: Calcium Chloride Anhydrous; Cupric Sulfate (CuSO4 5H2O); 0.0751 mg/L Ferric Nitrate (Fe(NO3) 9H2O); 0.0209 mg/L Ferric Sulfate (FeSO47H2O); 306.969 mg/L Potassium Chloride (KCl); 14.418 mg/L Magnesium Chloride (MgCl2); 63.237 mg/L Magnesium Sulfate (MgSO4); 5021.73 mg/L Sodium Chloride (NaCl); 1100 mg/L Sodium Bicarbonate (NaHCO4); 93.964 mg/L Sodium Phosphate Monobasic (NaH2PO4H2O); 35.753 mg/L Sodium Phosphate dibasic (Na2HPO4 7H2O); 0.217 mg/L Zinc Sulfate (ZnSO4 7H2); 3836.3 mg/L D-Glucose (Dextrose); 8.127 mg/L Phenol Red; 3099.505 mg/L HEPES; 1.203 mg/L Na Hypoxanthine; 0.0211 mg/L Linoleic acid; 0.0528 mg/L DL-68-Thioctic Acid; 0.0407 mg/L Sodium Putrescine 2HCl; 2.5×10-6 mg/L Putrescine 8 Sodium Selenite; 40.1885 mg/L Sodium Pyruvate; 3.24 mg/L Alanine; 116.255 mg/L Arginine HCl; 4.19 mg/L Asparagine; 3.347 mg/L Aspartic acid; 9.445 mg/L Cysteine H2O; 15.752 mg/L Cysteine 2HCl; 3.7 mg/L Glutamic acid; 293.55 mg/L Glutamine; 24.439 mg/L Glycine; 36.847 mg/L Histidine HCl H2O; 79.921 mg/L Isoleucine; 82.227 mg/L Leucine; 118.937 mg/L Lysine HCl; 23.679 mg/L Methionine; 50.861 mg/L Phenylalanine; 12.564 mg/L Proline; 34.214 mg/L Serine; 74.408 mg/L Threonine; 12.54 mg/L Tryptophan; 64.086 mg/L Tyrosine 2Na+2 H2O; 73.606 mg/L Valine; 0.00176 mg/L Biotin; 3.127 mg/L D-Calcium panthenate; 6.52 mg/L Choline chloride; 3.334 mg/L Folic acid; 9.904 mg/L i-Inositol; 3.079 mg/L Niacinamide; 3.022 mg/L Pyridoxine HCl; 0.31 mg/L Riboflavine; 3.092 mg/L Thiamine HCl; 0.183 mg/L Thymidine; and 0.512 mg/L Vitamin B12. 19. A method of preparing cryopreserved blood cell products for transplantation comprising: a) thawing a cryopreserved blood cell product; andb) transferring the thawed blood cell product to a composition comprising about 5% to about 10% dextran a chemically defined cell culture medium, and one or more cloned growth factors or cytokines; wherein said composition does not contain fetal calf serum or an animal-derived lipid. 20. The method of claim 19, wherein the dextran is selected from the group consisting of: dextran-1, dextran-10, dextran-20, dextran-30, and dextran-40. 21. The method of claim 20, wherein the composition comprises about 1% to about 10% HSA. 22. The method of claim 19, wherein the dextran is dextran-40. 23. The method of claim 19, wherein the composition comprises about 10% dextran. 24. The method of claim 19, wherein the chemically defined cell culture medium is selected from the group consisting of: Iscove's modified Dulbecco's medium (IMDM), Dulbecco's modified Eagle medium (DMEM), Roswell Park Memorial Institute medium (RPMI) 1640 medium, McCoy's 5A medium, minimum essential medium alpha medium (alpha-MEM), basal medium Eagle (BME), Fischer's medium, medium199, F-12K nutrient mixture medium (Kaighn's modification, F-12K), and X-vivo 20. 25. The method of claim 19, wherein the one or more cloned growth factors or cytokines are selected from the group consisting of: flt3-ligand (FLT3); thrombopoietin (TPO), stem cell factor (SCF), epidermal growth factor (EGF), transforming growth factor (TGF-β), basic fibroblast growth factor (bFGF), interleukin-3 (IL3), interleukin-6 (IL6), and interleukin-9 (IL9). 26. The method of claim 19, wherein the composition comprises an agent selected from the group consisting of a cAMP analogue or enhancer, a Gα-s activator, and a prostaglandin pathway agonist. 27. The method of claim 26, wherein the prostaglandin pathway agonist selectively binds the PGE2 EP2 or PGE2 EP4 receptor. 28. The method of claim 27, wherein the prostaglandin pathway agonist comprises PGE2, or a PGE2 analogue or a derivative. 29. The method of claim 27, wherein the prostaglandin pathway agonist is selected from the group consisting of: PGE2, 16,16-dmPGE2, 15(S)-15-methyl PGE2, 20-ethyl PGE2 and 8-iso-16-cyclohexyl-tetranor PGE2. 30. The method of claim 27, wherein the prostaglandin pathway agonist comprises 16,16-dmPGE2. 31. The method of claim 19, wherein the blood cell product is thawed at a temperature of about 20° C. to about 37° C. 32. The method of claim 31, wherein the blood cell product is thawed at a temperature of about 37° C. 33. The method of claim 19, wherein the blood cell product is selected from the group consisting of: bone marrow cells (BMCs), umbilical blood cells (UCBCs), placental blood cells, mobilized peripheral blood cells (mPBCs), hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), and CD34+ cells. 34. The method of claim 19, wherein the blood cell product comprises bone marrow, umbilical cord blood, placental blood, or mobilized peripheral blood. 35. The method of claim 19, wherein the blood cell product comprises purified population of CD34+ cells. 36. The method of claim 19, wherein the cell lysis of the blood cell products is decreased about 10% to about 50% compared to the cell lysis of a control blood cell product. 37. The method of claim 19, wherein the CD34+ cell viability of the blood cell product is increased about 10% to about 50% compared to the CD34+ cell viability of a control hematopoietic cell population. 38. The method of claim 19, wherein the TNC count of the blood cell product is increased about 10% to about 50% compared to the TNC count of a thawed control blood cell product that has been transferred to a control solution. 39. The method of claim 19, wherein the blood cell product is modulated ex vivo. 40. The method of claim 39, wherein the modulation comprises contacting the blood cell product with an agent selected from the group consisting of: a cAMP analogue or enhancer, a Gα-s activator, and a prostaglandin pathway agonist. 41. The method of claim 40, wherein the prostaglandin pathway agonist selectively binds the PGE2 EP2 or PGE2 EP4 receptor. 42. The method of claim 40, wherein the prostaglandin pathway agonist comprises PGE2, or a PGE2 analogue or derivative. 43. The method of claim 40, wherein the prostaglandin pathway agonist is selected from the group consisting of: PGE2, 16,16-dmPGE2, 15(S)-15-methyl PGE2, 20-ethyl PGE2, and 8-iso-16-cyclohexyl-tetranor PGE2. 44. The method of claim 40, wherein the prostaglandin pathway agonist comprises 16,16-dmPGE2. 45. The method of claim 40, wherein the blood cell product is contacted with the agent for a time of about one hour to about four hours. 46. The method of claim 40, wherein the blood cell product is contacted with the agent at a temperature of about 25° C. to about 37° C. 47. The method of claim 46, wherein the blood cell product is contacted with the agent at a temperature of about 37° C. 48. The method of claim 39, wherein engraftment of the blood cell product is increased in vivo, compared to a non-modulated blood cell product. 49. The method of claim 39, wherein reconstitution of the blood cell product is increased in vivo, compared to a non-modulated blood cell product. 50. The method of claim 39, wherein the homing of the blood cell product is increased in vivo, compared to a non-modulated blood cell product. 51. The method of claim 39, wherein proliferation of the blood cell product is increased in vivo, compared to a non-modulated blood cell product. 52. The method of claim 19, wherein the blood cell product is administered to a subject. 53. The method of claim 52, wherein the blood cell product is allogeneic to the subject. 54. The method of claim 52, wherein the blood cell product is autologous to the subject. 55. The method of claim 52, wherein the subject has a disease, disorder, or condition selected from the group consisting of: ischemia, a non malignant blood disorder, an immunodeficiency, severe combined immunodeficiency (SCID), lymphocytopenia, thrombocytopenia, neutropenia, anemia, Fanconi's anemia, severe aplastic anemia, a congenital hemoglobinopathy, sickle cell disease, β-thalassemaia, sickle-cell disease, Wiskott-Aldrich syndrome, a metabolic storage disease, Hurler's disease, Hunter's disease, mannosidosis, a cancer, a hematological malignancy, acute leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, myelodysplastic syndrome, a non-hematological cancer, breast cancer, ovarian cancer, brain cancer, prostate cancer, lung cancer, colon cancer, skin cancer, liver cancer, and pancreatic cancer.